nach oben

International Urogynecology Journal

Erschienen in:

13.01.2022 | Review Article

Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis

verfasst von: Sami Shawer, Aethele Khunda, Gareth J. Waring, Paul Ballard

Erschienen in: International Urogynecology Journal | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The association between overactive bladder (OAB) syndrome and sexual dysfunction is well documented. Intra-detrusor onabotulinumtoxinA (Botox) has proven to be effective treatment for OAB syndrome. Our aim was to examine the impact of intravesical Botox injection on sexual function in patients with OAB, by systematically reviewing the literature.

Methods

We reviewed the literature for studies that reported a change in sexual function after Botox treatment in patients suffering from OAB. This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement using pre-agreed keywords, from database inception to December 2020. Statistical analyses were performed using Review Manager (RevMan; v.5.4).

Results

Initial results yielded 455 citations. Seven articles met our inclusion criteria. One article was double-reported, leaving 6 studies in the systematic review. Three observational before-and-after studies used the Female Sexual Function Index (FSFI) with sufficient information, and therefore were included in our meta-analysis. The pooled number of participants in all studies was 119 patients. In the meta-analysis, there was significant improvement in the following domains of the FSFI after Botox injection; desire (mean difference (MD) −0.51, p = 0.02), arousal (MD −0.86, p = 0.02), lubrication (MD −0.57, p = 0.03), orgasm (MD −0.65, p = 0.0003) and satisfaction (MD −0.46, p = 0.05). Pain was the only domain that did not show improvement (MD −0.07, p = 0.79). The total FSFI score was reported in 88 patients (two studies) showing significant improvement (MD −0.77, p = 0.006).

Conclusions

We report a systematic review of the effect of Botox treatment on sexual function in patients with OAB. Although studies are small, the results indicate a positive effect in patients with OAB.

Abrams P, Andersson KE, Birder L, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40. https://doi.org/10.1002/nau.20870.CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 1314–5. https://doi.org/10.1016/j.eururo.2006.09.019.CrossRefPubMed

Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.PubMed

Perry S, McGrother CW, Turner K, Leicestershire MRC Incontinence Study Group. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol. 2006;11(Pt 3):463–82. https://doi.org/10.1348/135910705X60742.CrossRefPubMed

Sen I, Onaran M, Tan MO, Acar C, Camtosun A, Sozen S, Bozkirli I. Evaluation of sexual function in women with overactive bladder syndrome. Urol Int. 2007;78(2):112–5. https://doi.org/10.1159/000098066.CrossRefPubMed

Patel AS, O'Leary ML, Stein RJ, Leng WW, Chancellor MB, Patel SG, Borello-France D. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006;32(1):77–87. https://doi.org/10.1590/s1677-55382006000100014.CrossRefPubMed

Zahariou A, Karamouti M, Tyligada E, Papaioannou P. Sexual function in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2010;16(1):31–6. https://doi.org/10.1097/SPV.0b013e3181bf51eb.CrossRefPubMed

Jha S, Ammenbal M, Metwally M. Impact of incontinence surgery on sexual function: a systematic review and meta-analysis. J Sex Med. 2012;9(1):34–43. https://doi.org/10.1111/j.1743-6109.2011.02366.x.CrossRefPubMed

López Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodríguez A, Moreno Bencardino C. Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis. Urology. 2017;100:53–8. https://doi.org/10.1016/j.urology.2016.10.026.CrossRefPubMed

10.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.CrossRefPubMedPubMedCentral

11.

Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.CrossRefPubMedPubMedCentral

12.

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.CrossRefPubMed

13.

Giannantoni A, Gubbiotti M, et al. Effects of Onabotulinum toxin a intradetrusor injections on urinary symptoms and sexual life in women affected by multiple sclerosis: a prospective controlled study. J Neurol Neurophysiol. 2017;8(3):1000427. https://doi.org/10.4172/2155-9562.1000427.CrossRef

14.

Giannantoni A, Proietti S, Giusti G, et al. OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. World J Urol. 2015;33(12):2095–101. https://doi.org/10.1007/s00345-015-1578-4.CrossRefPubMed

15.

Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. https://doi.org/10.1016/j.juro.2012.12.022.CrossRefPubMed

16.

Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. https://doi.org/10.1016/j.eururo.2013.04.001.CrossRefPubMed

17.

Fowler CJ, Auerbach S, Ginsberg D, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57. https://doi.org/10.1016/j.eururo.2012.03.005.CrossRefPubMed

18.

Balzarro M, Rubilotta E, Braga A, et al. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228–31. https://doi.org/10.1016/j.ejogrb.2018.05.002.CrossRefPubMed

19.

Miotla P, Cartwright R, Skorupska K, et al. Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. Neurourol Urodyn. 2017;36(6):1564–9. https://doi.org/10.1002/nau.23148.CrossRefPubMed

20.

Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208. https://doi.org/10.1080/009262300278597.CrossRefPubMed

21.

Balzarro M, Rubilotta E, Mancini V, et al. Impact of overactive bladder-wet syndrome on female sexual function: a systematic review and meta-analysis. Sex Med Rev. 2019;7(4):565–74. https://doi.org/10.1016/j.sxmr.2019.05.002.CrossRefPubMed

22.

Levy G, Lowenstein L. Overactive bladder syndrome treatments and their effect on female sexual function: a review. Sex Med. 2020;8(1):1–7. https://doi.org/10.1016/j.esxm.2019.08.013.CrossRefPubMed

23.

Zachariou A, Mamoulakis C, Filiponi M, et al. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urol. 2018;18(1):61. https://doi.org/10.1186/s12894-018-0377-9.CrossRefPubMedPubMedCentral

24.

Del Rosso A, Pace G, Di Pierro ED, Masciovecchio S, Galatioto GP, Vicentini C. Impact of overactive bladder on sexual function in women. Urologia. 2011;78(3):200–2. https://doi.org/10.5301/RU.2011.8547.CrossRefPubMed

25.

Cakir SS, Degirmentepe RB, Atalay HA, et al. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. Int Urol Nephrol. 2019;51(1):27–32. https://doi.org/10.1007/s11255-018-2030-7.CrossRefPubMed

26.

Zachariou A, Filiponi M. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Int Braz J Urol. 2017;43(4):713–20. https://doi.org/10.1590/S1677-5538.IBJU.2016.0303.CrossRefPubMedPubMedCentral

27.

Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54. https://doi.org/10.1111/bju.12972.CrossRefPubMed

28.

Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature. Int Urogynecol J. 2019;30(3):339–52. https://doi.org/10.1007/s00192-018-3841-x.CrossRefPubMed

29.

Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16. https://doi.org/10.1002/nau.22251.CrossRefPubMed

30.

Kershaw V, Khunda A, McCormick C, Ballard P. The effect of percutaneous tibial nerve stimulation (PTNS) on sexual function: a systematic review and meta-analysis. Int Urogynecol J. 2019;30(10):1619–27. https://doi.org/10.1007/s00192-019-04027-3.CrossRefPubMed

31.

Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol. 2018;132(2):453–8. https://doi.org/10.1097/AOG.0000000000002733.CrossRefPubMed

Titel: Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis
verfasst von: Sami Shawer
Aethele Khunda
Gareth J. Waring
Paul Ballard
Publikationsdatum: 13.01.2022
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal / Ausgabe 2/2022
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-021-05072-7

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Healthcare utilization following minimally invasive apical prolapse repair in a large integrated healthcare system

Pelvic floor function and morphological abnormalities in primiparas with postpartum symptomatic stress urinary incontinence based on the type of delivery: a 1:1 matched case–control study

Surgical management of vaginal cancer and concomitant complete uterovaginal prolapse

British Society of Urogynaecology Abstracts: Annual Research Meeting November 2020

Racial disparities in complications and costs after surgery for pelvic organ prolapse

Large vaginal polyp post-Manchester repair masquerading as uterine prolapse

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie